GlassScriptPhysician profile
Amir Prushani
NPI 1275762858
$1,936.75
in general payments reported to CMS, 2019-2025
15 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $561 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,936.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $686.36 | 2024-2025 | |
| Janssen Biotech, INC. | $306.74 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $240.91 | 2024-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $135.96 | 2025 | |
| Phathom Pharmaceuticals, INC. | $118.03 | 2024-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $70.67 | 2025 | Iqirvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.77 | 2024-2025 | Xifaxan |
| Novo Nordisk INC | $54.27 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $46.37 | 2025 | Zenpep |
| Pfizer INC. | $45.83 | 2025 | |
| Madrigal Pharmaceuticals | $45.72 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $39.83 | 2025 | Dupixent |
| Lilly USA, LLC | $31.29 | 2025 | Omvoh |
| Qol Medical, LLC | $24.19 | 2024 | Sucraid |
| Organon LLC | $21.81 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Prushani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.